Skip to main content

Oruka Therapeutics

Oruka Therapeutics Inc is an American biotechnology enterprise focused on developing novel biologic therapies for chronic skin and inflammatory diseases. The company designs engineered monoclonal antibodies targeting validated cytokines, with a focus on delivering extended durability and convenient dosing regimens. Its key pipeline programs include ORKA-001, an interleukin-23 inhibitor, and ORKA-002, an interleukin-17 inhibitor designed for plaque psoriasis and related conditions. Operations revolve around preclinical asset optimization, protein engineering, bio-manufacturing, and clinical development management. As a development-stage biopharmaceutical entity, Oruka generates minimal commercial revenue and finances its operations through capital markets and private equity backing. The company holds an emerging position in targeted immunological therapies. Oruka Therapeutics is headquartered in Menlo Park, California, United States, and its common stock is traded on the Nasdaq Global Market.

10 of the funds FundTelligence covers report a position in Oruka Therapeutics.

Legal name
ORUKA THERAPEUTICS INC
Sector
Health Care
Country
United States
Funds holding it
10

Funds holding Oruka Therapeutics

Showing the 8 largest of 10 funds holding it.

Loading...